Kymriah 00078-0846-19
Generic: Tisagenlecleucel
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Dosage Form
- Injection, Suspension
- Route
- Intravenous
- Product Type
- Cellular Therapy
- Marketing Start
- August 30, 2017
- Listing Expires
- December 31, 2026
- Application
- BLA125646
Active Ingredients
| Ingredient | Strength |
|---|---|
| Tisagenlecleucel | 2000000 1/1 |
Drug Class
CD19-directed Chimeric Antigen Receptor [EPC]Genetically-modified Autologous T Cells [EPC]CD19 Receptor Interactions [MoA]
Selected Package
00078-0846-19Selected1 INJECTION, SUSPENSION in 1 BAG (0078-0846-19)